ING Group’s Emergent Biosolutions EBS Stock Holding History

ING Group’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-76,074	Closed	-$1.92M	–	656
2014 Q1	$1.92M	Hold	76,074	–	–	0.01%	491
2013 Q4	$1.75M	Sell	76,074 -8,337	-10%	-$174K	0.01%	490
2013 Q3	$1.61M	Hold	84,411	–	–	0.01%	518
2013 Q2	$1.22M	Buy	+84,411	New	+$1.22M	0.01%	532

Other funds holding EBS

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ING Group's EBS Position: Q2 2014 in Review

ING Group sold out of Emergent Biosolutions (EBS) in Q2 2014, closing a stake of 76,074 shares — an estimated $1.92M sold.

ING Group first reported a position in EBS in Q2 2013 and held it in 4 quarters. The position peaked at $1.92M in Q1 2014. 160 funds tracked by Wall St. Rank hold EBS as of Q2 2014.

ING Group reported no remaining Emergent Biosolutions position as of Q2 2014 after selling out during the quarter.
ING Group sold 76,074 Emergent Biosolutions shares in Q2 2014, an estimated $1.92M.
ING Group first reported a position in Emergent Biosolutions in Q2 2013 and held it in 4 quarters.
ING Group's Emergent Biosolutions position peaked at $1.92M in Q1 2014.
160 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2014.

Based on ING Group's 13F filing for Q2 2014, filed 14 Aug 2014.